By Angela McDaniels
Seattle, Nov. 8 - Mersana Therapeutics Inc. said it has completed an oversubscribed $21 million financing led by Fidelity Biosciences and ProQuest Investments.
Other investors included Rho Ventures, PureTech Ventures, Cape Family Fund LLC, Harris & Harris Group Inc. and Lansing Brown Investments LLC.
With completion of the financing, Jay Moorin and Joyce Tsang, partners at ProQuest Investments, Jason Rhodes, principal at Fidelity Biosciences, and Martin Vogelbaum, partner at Rho Ventures joined existing members Charles Harris of Harris & Harris Group and Mersana president and chief executive officer Julie Olson on the board of directors.
Mersana is based in Cambridge, Mass., where it develops therapeutic agents for the treatment of cancer.
| Issuer: | Mersana Therapeutics Inc.
|
| Amount: | $21 million
|
| Investors: | Fidelity Biosciences, ProQuest Investments (leads), Rho Ventures, PureTech Ventures, Cape Family Fund LLC, Harris & Harris Group Inc., Lansing Brown Investments LLC
|
| Announcement date: | Nov. 8
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
